Sankala Group
VERA icon

Sankala Group’s Vera Therapeutics VERA Stock Holding History

Sankala Group’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.98K Hold
61
– – ﹤0.01% 500
2026
Q2 		$1.96K Hold
61
– – ﹤0.01% 517
2026
Q1 		$2.38K Hold
61
– – ﹤0.01% 478
2025
Q4 		$2.49K Buy
+61
New +$2.17K ﹤0.01% 486

Other funds holding VERA

Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sankala Group's VERA Position: Q3 2026 in Review

Sankala Group held its Vera Therapeutics (VERA) position steady in Q3 2026 at 61 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #500.

Sankala Group first reported a position in VERA in Q4 2025 and has held it in 4 quarters since. The position peaked at $2.49K in Q4 2025. 71 funds tracked by Wall St. Rank hold VERA as of Q3 2026.

  • Sankala Group held 61 shares of Vera Therapeutics worth $1.98K as of Q3 2026.
  • Sankala Group left its Vera Therapeutics share count unchanged in Q3 2026.
  • Vera Therapeutics made up ﹤0.01% of Sankala Group's portfolio in Q3 2026, its #500 holding.
  • Sankala Group first reported a position in Vera Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Sankala Group's Vera Therapeutics position peaked at $2.49K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.